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The field of epilepsy genetics is advancing rapidly and epilepsy is emerging as a frequent
indication for diagnostic genetic testing. Within the larger ClinGen framework, the ClinGen
Epilepsy Gene Curation Expert Panel is tasked with connecting two increasingly separate fields:
the domain of traditional clinical epileptology, with its own established language and classification
criteria, and the rapidly evolving area of diagnostic genetic testing that adheres to formal criteria
for gene and variant curation. We identify critical components unique to the epilepsy gene curation
effort, including: (1) precise phenotype definitions within existing disease and phenotype
ontologies; (2) consideration of when epilepsy should be curated as a distinct disease entity; (3)
strategies for gene selection; and (4) emerging rules for evaluating functional models for seizure
disorders. Given that de novo variants play a prominent role in many of the epilepsies, sufficient
genetic evidence is often awarded early in the curation process. Therefore, the emphasis of gene
curation is frequently shifted towards an iterative precuration process to better capture phenotypic
associations. We demonstrate that within the spectrum of neurodevelopmental disorders, gene
curation for epilepsy-associated genes is feasible and suggest epilepsy-specific conventions, laying
the groundwork for a curation process of all major epilepsy-associated genes.

Keywords
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epilepsy; clinical validity; ClinGen/Clinical Genome Resource; gene-disease association; epileptic
encephalopathy

Background
Epilepsy is one of the most common brain disorders, affecting up to 3 million people in the
United States (US) with an annual cost to the US healthcare system of up to 15 billion USD.
Despite the availability of a growing number of anti-epileptic medications, up to 30% of
persons with epilepsy have treatment-resistant seizures, significantly impacting quality of
Hum Mutat. Author manuscript; available in PMC 2020 August 11.
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life and putting patients at risk for various comorbidities and complications including death
(Moshe, et al., 2015). Epilepsy can develop in the setting of structural changes to the brain
such as injuries or malformations. However, in a significant proportion of patients, no
structural alterations can be identified through neuroimaging (Thomas and Berkovic, 2014).
Twin studies demonstrate a strong genetic contribution to various epilepsy types, and family
studies suggest a strong genetic influence on a population level (Berkovic, et al., 1998;
Peljto, et al., 2014; Vadlamudi, et al., 2004). Novel technologies to generate large scale
genetic data have led to various breakthroughs in rare pediatric epilepsies, where precision
medicine approaches are already applied (Epi, et al., 2013; Epi, 2015; Euro, et al., 2017;
Reif, et al., 2017).

Author Manuscript

With the advent of next-generation sequencing technologies, the last decade has seen an
explosion of causative genes identified in patients with epilepsy and neurodevelopmental
disorders, and currently more than 40 genes are considered bona fide causes of genetic
epilepsies, given that pathogenic variants in these genes are identified in patients with
epilepsy on a regular basis in a clinical and research setting. Most of these genes are linked
to developmental and epileptic encephalopathies, severe epilepsies with an early age of onset
and multiple associated comorbidities. The genetic testing landscape is extremely diverse
ranging from targeted testing including single gene assays to exome or genome sequencing.
Targeted epilepsy gene panel approaches are equally diverse, with some focusing on bona
fide genes causing primary epilepsy and other larger gene panels often including genes
related to syndromic disorders or candidate genes related to epilepsy due to their cellular and
functional roles.

Author Manuscript
Author Manuscript

Given that epilepsy is a dynamic disease occurring over time, it is the hope in the field that
genetic findings can be used to guide therapy and improve patient outcomes (Epi, 2015).
However, using genetic data for patient treatment requires that genetic findings are
systematically vetted for the association with a given disease entity. While scientific
publications on gene discovery have a focus on novelty, there are few mechanisms to track
the emerging evidence for genes over time and to systematically assess their validity within
a disease context. The Clinical Genome Resource (ClinGen) Gene Curation Expert Panel
offers such a mechanism by providing an evidence-based framework to assess the clinical
validity of specific gene-disease associations using available genetic and experimental
evidence. ClinGen is an NIH-funded initiative dedicated to identifying clinically relevant
genes and variants for use in precision medicine and research (Rehm, et al., 2015). One of
the main tasks of the ClinGen Consortium is the assessment of the validity gene-disease
associations, asking the question whether variation in a certain gene has sufficient evidence
to be considered causative for a particular phenotype. To this end, the ClinGen Consortium
has developed a formal framework to evaluate genetic and experimental evidence supporting
or disputing a gene-disease relationship (Strande, et al., 2017). This framework will then
form the basis to assess variants within these genes based on guidelines, such as the
recommendations by the American College of Medical Genetics and Genomics (Richards, et
al., 2015). Deposition of variants in curated genes in public archives such as ClinVar
(Landrum, et al., 2016) will then allow variant information to be used in diagnostic and
research settings. However, prior to considering evidence for a particular variant and
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considering potential actionability of genetic testing, sufficient evidence for the involvement
of a gene within the context of a particular disease needs to be established.
The ClinGen Epilepsy Gene Curation Expert Panel is tasked with assessing the validity of
gene-disease associations related to human epilepsy within the formal, evidence-based gene
curation framework of the wider ClinGen Consortium, with the ultimate goal that these
findings will inform future decisions about gene selection for diagnostic tests and future
studies into precision medicine approaches. In parallel, the epilepsy field has a rich tradition
in studying genetic causes of human epilepsy that is traditionally focused on phenotyping.
The current manuscript describes the pilot activities during the first year of the ClinGen
Epilepsy Gene Curation Expert Panel, with an emphasis on harmonization between
traditional clinical epilepsy concepts and the ClinGen framework to lay the groundwork for
a larger gene curation effort in the future.

Author Manuscript

Methods and Results
Composition of the ClinGen Epilepsy Gene Curation Expert Panel

Author Manuscript

The ClinGen Epilepsy Gene Curation Expert Panel has been active since June 2017 and
consists of a mixture of clinical epileptologists, medical geneticists, genetic counselors,
clinical molecular geneticists, basic scientists, and biocurators. The composition of the
working group is international, with members from the US, Europe, and Canada. The
ClinGen Epilepsy Gene Curation Expert Panel is embedded within the ClinGen
Neurodevelopmental Disorders Clinical Domain Working Group (CDWG) that also includes
the Intellectual Disability/Autism Gene Curation Expert Panel and the Rett/Angelman-like
disorders Variant Curation Expert Panel. Two epilepsy gene-specific variant curation expert
panels are planned as future components of the Neurodevelopmental Disorders CDWG
including the KCNQ2 Expert Panel and the NMDA receptor Variant Curation Expert Panel
(GRIN1, GRIN2A, GRIN2B, GRIN2D). The ClinGen Epilepsy Gene Curation Expert Panel
is also affiliated with the International League Against Epilepsy (ILAE) Genetics
Commissions through prior membership in the Genetics Commission during the 2014–2017
for Ingo Helbig and Heather Mefford and current affiliation for the 2017–2020 term through
the “Epilepsiome” Task Force, linking the ClinGen gene curation activities with the genetic
literacy series of the ILAE Genetics Commission (Helbig, et al., 2016; Tan, et al., 2015) and
peer-to-peer communication through a dedicated blog (“Beyond the Ion Channel”;
epilepsygenetics.net).
Strategies of gene selection

Author Manuscript

Within the expert panels of the Neurodevelopmental Disorders CDWG, various strategies
were used to select a set of genes for initial curation (Figure 1). Given the frequent use of
dedicated gene panels in a clinical setting, the epilepsy expert panel decided to focus on a
limited number of genes as the first goal of gene curation, curating the “average gene panel”
used in clinical practice. In order to identify commonly tested genes, we compiled a list of
2,702 genes from 236 commercial gene panels through a query of the Genetic Testing
Registry for tests with the keywords “seizure OR epilepsy” (Rubinstein, et al., 2013). In
order to select genes with a primary epilepsy phenotype as opposed to genes with epilepsy
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as a contributing feature, we compiled a condensed gene list of 123 genes, combining
evidence from literature (Heyne, et al., 2018; Lindy, et al., 2018), and expert opinion. Out of
this gene list, 29 genes were selected for the pilot phase and for the precuration process, a
review of published phenotypes prior to initiating the formal curation process (discussed
below). Genes with primary syndromic or non-epilepsy neurodevelopmental phenotypes
including autism and intellectual disability were excluded, such as ZEB2 for Mowat-Wilson
Syndrome. In addition, genes primarily associated with a Rett-like phenotype such as
MECP2 or CDKL5 were removed from the gene list, given the existence of a dedicated
working group for these conditions within ClinGen. For some genes, an iterative review after
a primary curation has revealed that further precuration is required to determine the clinical
validity of gene for a specific epilepsy phenotype (example GRIN1). The list of precurated
genes will then undergo a formal gene curation process after selecting and possibly refining
an adequate epilepsy phenotype within the MONDO disease ontology (Figure 2). The pilot
phase of the ClinGen Epilepsy Expert Panel highlighted issues related to traditional clinical
epilepsy classification for which we developed an iterative process to systematically curate
epilepsy-associated genes, which is currently in process.
Piloting epilepsy gene curation

Author Manuscript

The ClinGen gene curation framework uses a dedicated gene curation interface (GCI) and
Monarch Disease Ontology (MONDO) for the specification of the disease entity of interest.
During the first year, an iterative process was adopted to initiate gene curation on a few
select genes to evaluate the ClinGen gene curation framework and its dedicated tools as they
apply specifically to the epilepsies. The pilot evaluation phase led to a process of curation
and precuration and an interactive process of defining the most appropriate grouping of
phenotypes for downstream gene curation. Using the previously-described evidence-based
framework from the ClinGen Gene Curation Working Group (Strande, et al., 2017), we
evaluated the clinical validity for the proposed gene-disease relationships for 16 genes
(Table 1). The ClinGen clinical validity framework uses two main classes of available
evidence, both genetic and experimental, to derive a semi-quantitative measurement of the
strength of the evidence for gene-disease associations. The classifications of the strength of
the gene-disease relationship include: “Definitive”, “Strong”, “Moderate”, “Limited”, “No
Reported Evidence”, and “Disputed”. In order to achieve a classification of “Definitive”, a
gene-disease association must achieve at least 12 points and demonstrate replication over
time, which is defined as at least two publications reporting pathogenic variants in the gene
and at least three years since the initial report. Our curation of the initial 16 genes resulted in
a classification as “Definitive” gene-disease association in 7/16 genes, “Strong” in 1/16
genes, “Limited” in 3/16 genes, and “Disputed” in 5/16 genes (Table 1).

Author Manuscript

Genetic evidence
Within the ClinGen gene curation framework, genetic evidence is derived from publicly
available data describing variants in the gene of interest identified in patients with the
disease entity of interest. Genetic evidence is divided into two categories: (1) case-level data,
in which studies report individuals or families with genetic variants; and (2) case-control
data, which is derived using statistical analyses in case-control studies. A maximum score of
12 points can be achieved through genetic evidence, with points awarded for variant
Hum Mutat. Author manuscript; available in PMC 2020 August 11.
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segregation and type for case-level data; and methodology, statistical power, bias and
confounding factors, and statistical significance for case-control data. Inheritance pattern
within reported cases is a strong consideration when assessing available case-level genetic
evidence, and in this regard the underlying genetic architecture of early-life epilepsies, with
a strong contribution of de novo variants, lends itself to achieving a high number of points
for case-level genetic evidence. Eight out of 16 genes in our pilot curation phase achieved
maximum genetic evidence of 12 points within the existing ClinGen gene curation
framework, which suggests that sufficient genetic evidence according to ClinGen criteria is
easily achieved both for well-established genetic causes of epilepsy including SCN8A and
KCNQ2 and more recently implicated genes such as KCNA2 and ALG13 (Supp. Table S1).
However, we also identified eight genes with limited or disputed evidence, suggesting that
some of the genes traditionally considered genetic etiologies for epilepsy have limited or
even contradictory evidence. For example, genes such as EFHC1 or CACNA1H are disputed
by formal ClinGen criteria, despite the fact that these genes are part of currently available
diagnostic gene panels (EFHC1 n=33 gene panels, CACNA1H n=13 gene panels). Most
genetic epilepsies have been described within the last five years in next-generation
sequencing studies, allowing for comparison of variant frequencies in patients with
population databases such as ExAC and gnomAD (Lek, et al., 2016), which can be used as
control populations for severe early-onset epilepsies. Therefore, minor allele frequencies in
control populations, segregation, and absence of other explanatory genetic etiologies are
frequently available and not a limiting factor in assessing gene validity within the epilepsies.
Within the context of the traditional clinical concept of genetic epilepsies, the existing
ClinGen clinical validity criteria were found to be adequate and to be reflective of the
general consensus in the epilepsy field.

Author Manuscript
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During our initial pilot curation phase, the expert panel noted that within the epilepsies, the
development of gene-specific assessment criteria may be helpful, both for gene curation and
variant interpretation. For example, a majority of known genetic epilepsies are considered
“channelopathies”, resulting from pathogenic variants in neuronal ion channel encoding
genes, often with a gain-of-function effect (Oyrer, et al., 2018). Consequently, loss-offunction variants, which are typically considered damaging or pathogenic in most genes,
may actually be tolerated in many neuronal ion channels or result in milder phenotypes, as is
the case in KCNQ2 (Miceli, et al., 1993). Domain knowledge, both of expected clinical
phenotypes for genetic epilepsy syndromes as well as expected variants and functional
consequences, is essential in appropriately interpreting the significance of epilepsyassociated variants. A future goal of the ClinGen Epilepsy Gene Curation Expert Panel is to
develop gene-specific assessment criteria in the context of the epilepsies, taking these and
other considerations into account, which will aid in curation both of gene-disease
associations as well as variant interpretation.
The expert panel has not yet considered gene-disease relationships where gene validity was
primarily asserted through association studies. Evaluation of case-control data will be
particularly relevant for milder, complex genetic epilepsies including the genetic generalized
epilepsies and non-lesional focal epilepsies, where monogenic factors play a role in a
minority of patients. Future curation efforts taking into account genetic evidence derived
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from case-control studies will allow the expert panel to assess its applicability to epilepsies
with a complex underlying genetic architecture.
Experimental evidence
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Gene-level experimental evidence is derived within the ClinGen framework by assessing the
following types of available evidence: biochemical function, experimental protein
interactions, expression, functional alteration in patient and non-patient derived cells,
phenotypic rescue, and animal model systems (Strande, et al., 2017). A maximum of six
points can be achieved from experimental evidence, taking various factors into account
including, but not limited to, the relevance and robustness of the experimental assay.
Experimental evidence in the eight genes with strong or definite evidence assessed during
the pilot curation phase ranged from absent to the full amount of six possible points (Table
1). Only one gene-disease association was awarded no points for experimental evidence, due
to lack of available evidence. The remaining seven genes were awarded some experimental
evidence points, ranging from two to six points. The types of experimental evidence used to
assess the gene-disease associations were highly variable, including biochemical function,
expression, functional alteration (largely in non-patient cells), and animal models (Supp.
Table S1). Although the neuroscience field has a strong tradition of functional studies in
neuronal ion channels (Oyrer, et al., 2018), the pilot curation phase did not reflect a bias
towards experimental evidence for ion channel genes; experimental evidence points were
also awarded for non-ion channel encoding genes including DNM1, CHD2, and STXBP1,
although notably not ALG13. However, experimental evidence was not needed to obtain
sufficient points for the classification of genes as definitive or strong for any of the eight
genes with strong or definite evidence curated within our pilot phase. This indicates that the
evidence for gene validity in the epilepsy field is primarily driven by genetic findings due to
the large number of published studies and a high proportion of genetic epilepsies due to de
novo variants and thus generally do not require experimental evidence as support.

Author Manuscript

The ClinGen gene curation framework is used as a guide, and in certain scenarios it is
appropriate for the expert panel to adjust scoring or final classifications based on
professional judgment. Given this consideration and the complexity of neurodevelopmental
phenotypes, the expert panel decided to award reduced points for experimental evidence in
some scenarios. For example, for KCNA2, the main mouse model has an ataxia phenotype
but not a seizure phenotype (Xie, et al., 2010). While ataxia is increasingly recognized as a
common feature in patients with KCNA2-related neurodevelopmental disorders, the question
arises how related phenotypic features should be scored within the concept of primarily
assessing functional evidence towards the epilepsy phenotype. Within the working group, it
was agreed that the presence of incomplete neurological phenotypes in model systems,
which may include movement disorders, would be scored at 0.5 compared to the default of 2
points for animal models that exhibit spontaneous seizures.
Use of disease and phenotype ontologies
Within the ClinGen framework, curation for a gene-disease association requires the selection
of a disease entity for which a given gene is curated. Disease entities within the ClinGen
framework are coded within the Monarch Disease Ontology (MONDO) [https://
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www.ebi.ac.uk/ols/ontologies/mondo], an aggregate ontology of human disease phenotypes
using a hierarchical concept of parent and child terms (Figure 2). While MONDO includes
epilepsy syndromes, the human phenotype ontology (HPO) is an ontology of symptoms,
which, in the context of epilepsies, would include seizure types and defined comorbidities
such as intellectual disability or movement disorders. Epilepsy is a field with a rich tradition
focused on electroclinical phenotyping, and the concept of using disease and phenotype
ontology is relatively new. Only some research initiatives such as the EuroEPINOMICSRES consortium have consistently used HPO terms and have been involved in the generation
of these ontologies (Kohler, et al., 2014; Kohler, et al., 2017).
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Disease and phenotype ontologies have often been generated through a computational data
aggregation process that may result in inconsistencies with existing clinical classifications at
the level of individual disease phenotypes. We identified a lack of correspondence of known
disease entities in MONDO with the current and previous ILAE classification of the
epilepsies (Scheffer, et al., 2017), indicating the need to align the MONDO ontology with
classifications that are used clinically and in epilepsy genetics research, such as the 2017
ILAE (Figure 2). We identified concepts within the ILAE classification that cannot be easily
translated into a disease ontology primarily defined by phenotypic features such as
MONDO. While many epilepsy syndromes can be mapped onto the MONDO ontology, the
classification of epilepsy by etiology, for instance, cannot be easily translated to the
MONDO ontology. Figure 2 demonstrates the differences in classification for Dravet
Syndrome (MONDO_0011794). Within the 2017 ILAE classification, seizure types,
epilepsy types, and epilepsy syndromes are classified on different levels, whereas the
MONDO ontology provides various parent terms for Dravet Syndrome, reflecting the use of
this epilepsy syndrome in various contexts. Within the ILAE classification, epilepsy
syndromes are referred to as clusters of clinical, EEG, or imaging features, but once a
diagnosis of a specific syndrome is made it is not defined to which broader parent term the
syndrome belongs to. However, such a hierarchical structure is the basis of the MONDO
ontology.
Iterative curation of epilepsy-related genes

Author Manuscript

Precuration—In complex neurodevelopmental disorders, the review of associated
phenotypes led to an iterative process of curation including a precuration step. The ClinGen
Lumping and Splitting Working Group has developed precuration guidelines that have been
used by the epilepsy expert panel in precuration efforts during our pilot phase (https://
www.clinicalgenome.org/working-groups/lumping-and-splitting/). The precuration process
includes a review of published phenotypes prior to launching the gene curation process,
leading to a possible assertion of distinct phenotypes versus disease spectrums, which is then
substantiated or refuted during the precuration review of the evidence for or against distinct
phenotypes. For a range of disease genes, a spectrum of disease entities has been observed,
sometimes even with distinct disease entities associated with identical variants.
During the curation of the 16 epilepsy-related genes and selection of 27 additional genes for
precuration in the pilot phase, we observed that traditional clinical distinctions between
known disease entities may not necessarily apply when using the ClinGen framework for
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genetic etiologies associated with epilepsy. A “variant first” approach to lumping and
splitting of epilepsy phenotypes is conceptually different from the “phenotype first”
approach in a clinical setting, and it may not be sensitive to known distinctions between
clinical entities if the variants overlap. For example, in the case of SCN1A-related disorders,
there is a traditional clinical distinction between Dravet Syndrome, a distinct developmental
and epileptic encephalopathy that presents in the first year of life, and other forms of
generalized epilepsy as a milder phenotype (Steel, et al., 2017; Zhang, et al., 2017).
However, as there are at least some families reported with overlapping phenotypes
associated with the same variant (Goldberg-Stern, et al., 2014; Hoffman-Zacharska, et al.,
2015), SCN1A-related disorders would be primarily considered a spectrum and would be
curated for a broad rather than narrow phenotype. Similar observations were made for genes
such as SCN2A and SCN8A. Alternatively, some gene-disease associations emerged as
distinct phenotypes that were less apparent at the outset. For example, in ALG13, strong
evidence emerged for an epilepsy phenotype in females with a recurrent de novo variant.
However, only limited evidence arose for the congenital disorders of glycosylation
phenotype that was first described and that is consistent with the presumed function of this
gene. Due to the accrual of genetic evidence through multiple reports, the female epileptic
encephalopathy phenotype that was initially considered a sub-phenotype, has “overtaken”
the initial ALG13 phenotype with respect to gene validity. Finally, some genes behaved as
expected in the precuration process. For example, for KCNQ2, precuration successfully
identified both the mild phenotype due to haploinsufficiency and the more severe phenotype
primarily associated with missense variants with predicted dominant-negative effect,
mirroring the separation between known clinical entities, Self-Limited Neonatal Seizures
(also known as Benign Familial Neonatal Epilepsy) and KCNQ2 encephalopathy, within the
ClinGen precuration framework.

Author Manuscript

Discussion
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In the current manuscript, we describe the pilot phase of the epilepsy gene curation activities
within the ClinGen Epilepsy Gene Curation Expert Panel. We demonstrate that the
established gene curation process can be applied to genetic etiologies linked to human
epilepsy with special considerations. We observe that genetic evidence for a selection of
epilepsy genes in the pilot phase can be readily provided through the published literature.
Both the de novo architecture of neurodevelopmental disorders as well as the high frequency
of follow-up publications focusing on phenotype delineation contribute to this effect.
However, other genes frequently tested on diagnostic gene panels have contradictory
evidence, and the gene-disease relationships must be considered disputed by the formal
criteria of the ClinGen consortium (CACNA1H, CACNB4, EFHC1, MAGI2, SRPX2).
Three genes curated within the pilot phase have limited evidence (GRIN2D, RYR3,
SCN9A), indicating that more evidence is needed to support a strong or definite genedisease association within the context of epilepsy. We identify the appropriate selection of
the disease phenotype as one of the major challenges in the curation effort, an activity that is
usually referred to as pre-curation.
In contrast to many other disease entities, the epilepsies are phenotypes that are not easily
classified within the existing ontologies and format, requiring the ClinGen Epilepsy Gene
Hum Mutat. Author manuscript; available in PMC 2020 August 11.
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Curation Expert Panel to put a strong focus on the precuration effort. Given that both the
MONDO and HPO classifications are increasingly used in a diagnostic context, we highlight
the importance of iteratively improving existing ontologies to align these classifications with
the classifications used in a clinical setting. In other words, classifications used for
diagnosing genetic epilepsies should harmonize with the schema used by the epileptologists
who treat these patients.
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Within the formal ClinGen framework, assessment of gene validity precedes the
interpretation on the variant level according to variant classification guidelines such as the
ACMG recommendations. However, particularly for the well-studied ion channel genes,
identified variants have been demonstrated to have variable, if not, opposite functional
effects. For example, disease-causing gain-of-function and loss-of-function variants are
observed in genes such as SCN2A or SCN8A. This observation raises the issue whether the
variant-level interpretation can be separated from the gene-level interpretation. The ClinGen
Consortium has addressed this question by providing recommendations on when phenotypes
linked to a particular gene should be lumped into a single phenotypic spectrum or split into
separate phenotypes (https://www.clinicalgenome.org/working-groups/lumping-andsplitting/). The identification of appropriate phenotypes is part of the precuration effort,
further emphasizing the need for a detailed precuration phase for epilepsy-related genes. We
have assessed this question for SCN8A where both gain-of-function and loss-of-function
variants have been described in the literature. We concluded that the SCN8A-related
disorders demonstrate a broad spectrum independent of the functional effect of the variant,
including variable presentations for known recurrent variants. With increasing knowledge
about different phenotypes, outcomes, and therapeutic responses, some of the curated genes
may have sufficient evidence to be split into distinct phenotypes in the future.
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Harmonizing traditional epilepsy phenotypes with the phenotypic categories provided by the
MONDO ontology provided a particular challenge and for some phenotypes, the existing
disease ontologies were insufficient. For example, the diagnostic term Early Infantile
Epileptic Encephalopathy is increasingly used both in a clinical and diagnostic setting, but
the term as defined by the MONDO disease ontology does not match the accepted clinical
definition for this term. In order to overcome the present mismatches between existing
clinical classifications and MONDO, the members of the ClinGen Epilepsy Gene Curation
Expert Panel have agreed on using specific terms such as “Early Infantile Epileptic
Encephalopathy” (MONDO ID:0016021) as placeholder terms for agreed-upon clinical
concepts such as Developmental and Epileptic Encephalopathy despite some inconsistency
of parent and child terms within the current ontology while ongoing collaboration with the
MONDO consortium continues in order to better define epilepsy-related syndromes that
resemble existing clinical classifications such as the ILAE classification within the MONDO
etiology. We recognize that the term “Epileptic Encephalopathy” as it is used for our gene
curation purposes is an imperfect placeholder and does not reflect the full clinical spectrum
of the genetic epilepsies that have been curated, nor does it necessarily accurately reflect the
clinical concept of an epileptic encephalopathy (Howell, et al., 2016). However, given that
the MONDO disease ontology is interlinked with corresponding HPO terms that are used in
many diagnostic laboratories to define the phenotypic overlap of specific genetic variants,
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aligning clinical classifications with ontologies used in laboratory diagnostics is an
important prerequisite for meaningful gene and variant interpretation in a diagnostic setting.
The corollary of this process is that the task of the Epilepsy Gene Curation Expert Panel is
expanding, shifting from a traditional gene curation platform to an initiative to systematize
the representation of epilepsy-related terminology in disease- and phenotype ontologies that
will provide the basis for bioinformatic assessments of phenotypic overlaps. The iterative
process of refining ontological entities prior to gene curation is unique to the ClinGen
Epilepsy Gene Curation Expert Panel and reflects the traditional focus on phenotyping
within the epilepsy field.

Author Manuscript

Going forward, the ClinGen Epilepsy Gene Curation Expert Panel will curate all major
genes related to human epilepsies in a systematic fashion to suggest gene-specific variant
curation criteria that will help reduce the high burden of variants of uncertain significance.
This will aid the ultimate goal of providing a framework for accurately assessing variant
pathogenicity for future precision medicine interventions.
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Figure 1.
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Gene selection and precuration process within the ClinGen Epilepsy Gene Curation Expert
Panel. Starting with a broad candidate list of genes compiled from genes available on
commercial gene panel (n=2702) the possible candidate genes are narrowed down and
supplemented by genes with diagnostic relevance, genes with statistical evidence and genes
suggested by expert opinion. This selection process provides a narrower list of candidate
genes, including 123 candidate genes as of April 2018. This list of candidates is dynamic
and may integrate further genes once evidence for these genes arises. From the 123
candidate genes, 29 genes were selected for the pilot phase of the ClinGen Epilepsy Gene
Curation Expert Panel for an iterative precuration process, during which the phenotypic
spectrum of genes was reviewed. Genes with primary phenotypes reviewed in other working
groups or expert panels were excluded and genes with dual phenotypes were selected to be
curated for a primary epilepsy phenotype. These genes are then carried forward for a
standard ClinGen gene curation process. During the pilot phase, a small selection of genes
was chosen to refine rules for genetic and experimental evidence and selection and, if
necessary, modification of MONDO terms.
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Figure 2.
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Differences between then MONDO ontology used in the ClinGen gene curation process and
the International League Against Epilepsy (ILAE) classification, using the example of
Dravet Syndrome (MONDO_0011794. Within the MONDO classification, the term Dravet
Syndrome has both parent terms and child terms. The parent terms are different clinical and
genetic concepts that comprise Dravet Syndrome as an entity, such as “Infantile Epilepsy
Syndrome” (MONDO_0020071) or “Infancy electroclinical syndrome” (MONDO_000413).
The term Dravet Syndrome is synonymous with Early Infantile Epileptic Encephalopathy
(EIEE), type 6 (SCN1A) and has two child terms, EIEE4 (STXBP1) and EIEE19
(GABRA1). Within the ILAE classification, seizure types, epilepsy types, and epilepsy
syndromes are classified on three levels, defining seizures types (generalized and occasional
focal seizures in Dravet Syndrome), epilepsy types (generalized epilepsy), and epilepsy
syndrome. The ILAE classification does not formally classify epilepsy syndromes by
diagnostic criteria, but states that electroclinical syndromes are clusters of features
incorporating seizure types, EEG and imaging features that tend to occur together, referring
to the ILAE educational resource epilepsydiagnosis.org that provides examples, diagnostic
parameters, review videos of seizure types and the EEG features of many established
syndromes, including Dravet Syndrome. In addition, the ILAE classification suggests to
provide an etiology for each level, including a genetic etiology.
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